Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ: CGTX )

0.6260 -0.0040 (-0.63%)
Streaming Delayed Price Updated: 12:28 PM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,551,553
Open 0.6300
Bid (Size) 0.6226 (9)
Ask (Size) 0.6296 (30)
Prev. Close 0.6300
Today's Range 0.5713 - 0.6300
52wk Range 0.3400 - 2.950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial
Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial 
Via News Direct
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga

Performance

YTD
-67.73%
-67.73%
1 Month
+46.36%
+46.36%
3 Month
+20.27%
+20.27%
6 Month
-66.16%
-66.16%
1 Year
-64.43%
-64.43%

More News

Read More
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?
Via Benzinga
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for November 14th
From Virtual Investor Conferences
Via GlobeNewswire
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
From Cognition Therapeutics, Inc.
Via GlobeNewswire
November’s Small-Cap Treasures: 3 Stocks Poised for Growth
Via MarketBeat
Topics Economy
Exposures Economy
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Dow Edges Lower; Ventyx Biosciences Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.